Novartis wins FDA approval of first oral MS drug

The (FDA) has approved the first oral drug for treating the most common form of multiple sclerosis.  Novartis received FDA advisory committee approval by a unanimous vote in June, and now the drug has the FDA’s approval for patient treatment.  Unlike current MS drugs which are given by injections or infusion, this new drug, called Gilenya (fingolimod) comes in a convenient daily capsule dosage form.

Multiple Sclerosis affects about 2.5 million people in the world & over 400,000 in the United States alone.  What causes MS is still not known & Gilenya is not a cure but a treatment to lessen the progression and symptoms of MS.  According to Novartis, Gilenya can cut the relapse rate of patients by more than 60%.


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: